Followers | 195 |
Posts | 24373 |
Boards Moderated | 0 |
Alias Born | 04/03/2010 |
Saturday, March 02, 2024 1:25:28 PM
“A group of Wall Street traders maliciously drove down the share price of a Maryland biotech with a promising new brain cancer vaccine, in pursuit of the marginal profits to be made by buying the stock cheaply and selling it back to the market.
In other words, if Citadel Securities and its ilk are to beat this case and prevent a string of copycat suits, they will probably have to give the rest of us more of a peek behind the curtain.
In a line that seemed destined to make its way on to the r/wallstreetbets message boards on Reddit, Stein further called the claims “cogent and at least as compelling as the inference that defendants were simply engaged in legitimate trading activity.”
https://beamstart.com/news/spoofing-case-might-draw-back-17093564962934
I did have a subscription to FT. But it’s not needed at the current time.
And here is another summary:
“EQUITIES
Allegations of Market Manipulation Against NWBO Spark Legal Battle
NWBO's 'spoofing' lawsuit against top broker-dealers dismissed but court sees potential for case to reveal high-speed trading practices.
?
13 hours ago
Key Takeaway
Northwest Biotherapeutics accuses Virtu and Citadel Securities of "spoofing" to lower NWBO stock, despite positive trials.
Manhattan court dismisses case against Citadel due to lack of evidence but acknowledges the plausibility of NWBO's claims.
NWBO's planned refiling could expose high-frequency trading practices, signaling a shift in handling market manipulation allegations.
Allegations of Market Manipulation
Northwest Biotherapeutics has accused seven broker-dealers, including Virtu and Citadel Securities, of engaging in "repeated spoofing" to drive down the share price of NWBO. The company alleged that these firms placed millions of sell orders they had no intention of fulfilling, leading to a significant drop in NWBO's valuation despite positive clinical trial results. The lawsuit sparked interest among Redditors, who speculated about hedge funds' motives and governance issues within NWBO.
Read more in other views:
POSITIVE
Innovative NWBO's Brain Cancer Vaccine Draws Investor Support Amid Legal Drama
NEGATIVE
Market Manipulation Allegations Cast Shadow Over Northwest Biotherapeutics' Share Price
Legal Developments
A Manhattan court recently dismissed NWBO's case against Citadel and others, citing a lack of evidence tying the alleged trading to specific losses. However, the court acknowledged the plausibility of most of NWBO's claims, suggesting that the case could proceed further. Magistrate Gary Stein found the distinction between cancelled and reduced orders unconvincing and noted the potential impact of defendants' conduct on NWBO's stock price.
Market Impact and Future Actions
NWBO plans to refile its complaint, potentially leading to the discovery process where internal records and communications from the defendants could be revealed. The outcome of this case could shed light on the practices of high-frequency trading firms and their influence on global markets. While Citadel Securities dismissed the lawsuit as malicious, the court's decision signals a shift in the default stance of market-makers regarding allegations of market manipulation.”
https://wallstreetnow.co/en/articles/2024/03/02/allegations-of-market-manipulation-against-nwbo-spark-legal-battle
Making waves…
‘Spoofing’ case might draw back curtain on high-speed trading firms https://t.co/vjHn2BPLeM | opinion
— Financial Times (@FT) March 2, 2024
I own NWBO. My posts on iHub are always posted expressly as just my humble opinion (IMHO) and none are advice, just my opinion. I am NOT a financial advisor, and it is assumed that everyone is responsible for their own due diligence.
Recent NWBO News
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM